Rat Model Market - Global Key Players, Trends, Industry Size & Forecast

By Author: robert henric
Total Articles: 492
Comment this article

The Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the market. The rat model market is expanding with the increase in R&D activities in pharmaceutical industries. These rat model are being used in many applications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines).

According to the new market research report “Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast” published by MarketsandMarkets™.

Expected Revenue Surge: The rat model market is expected to reach USD 588.9 million, at a CAGR of 8.7%

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76036494

The development of advanced rat ...
... genome manipulation techniques (such as creation of transgenic rats and knockout rats), drives the global rat model market;

Preclinical animal models, such as mice and rats that are used to predict drug efficacy and toxicity in humans, are needed. Rats are commonly used due to their genetic similarity to humans as well as their unlimited supply and ease of manipulation. Knockout rats are produced by inactivating/silencing or “knocking out” an existing gene and replacing it with an artificial piece of DNA, thereby resulting in the loss of gene activity. This leads to changes in the rat’s phenotypic characteristics, such as appearance, behavior, and other observable biochemical characteristicsc. Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson’s.

DIABETES;

Rats are considered to be excellent experimental models for understanding the complex genetic basis of diseases such as diabetes. Due to the ever-increasing prevalence of diabetes globally; it has become important to study the mechanism of the disease. However, it is quite difficult to carry out research studies in human beings, owing to problems such as genetic heterogeneity and lack of controlled lifestyles. Rat models act as suitable models to study specific genetic mutations and to understand the function of genes on a homogeneous genetic background.

IMMUNOLOGY AND INFLAMMATION;

Rat models are used in immunology and inflammation studies as they help to assess the physiological relevance of an experimental finding. They also assist in identifying the functions of newly identified surface receptors in host defense as well as the developmental consequences of a disturbed signaling pathway or removing a transcription factor.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76036494

Major Rat Model Market Developments;

– In August 2016, Charles River Laboratories, Inc. entered into a strategic partnership with The Milner Therapeutics Institute and Consortium (UK). This partnership with the Consortium allows the academic institutions access to Charles River’s early discovery and drug development and services for the early stage drug development processes.

– In September, 2016, Charles River Laboratories International, Inc. acquired Agilux Laboratories (US), a provider of bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. This acquisition is expected to compliment Charles River’s non-clinical portfolio and improve the clients’ early-stage research efforts by enabling them to seamlessly transition their drug candidates through the discovery and safety assessment process.